New study aims to find best CMV prevention for kidney transplant patients

NCT ID NCT06798909

Recruiting now Prevention Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two different approaches to prevent cytomegalovirus (CMV) disease in adults who have received a kidney from a CMV-positive donor but are themselves CMV-negative. One group will take daily antiviral medicine for 200 days after transplant, while the other group will have weekly blood tests and only take medicine if the virus appears. The goal is to see which method better prevents CMV disease in the first year after transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney disorder cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS (CMV) KIDNEY DISEASES KIDNEY TRANSPLANT; COMPLICATIONS

Contacts and locations

Locations

Emory University School of Medicine
RECRUITING

Atlanta, Georgia, 30322, United States
Medical College of Virginia Commonwealth
RECRUITING

Richmond, Virginia, 23219, United States
Robert Wood Johnson Health Network Barnabas Health
RECRUITING

Livingston, New Jersey, 07039, United States
University of California, San Francisco School of Medicine
RECRUITING

San Francisco, California, 94117, United States
University of Miami Miller School of Medicine
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.